(Q24247966)

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Chemotherapy for metastatic soft tissue sarcomas – another full circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Chemotherapy of advanced soft-tissue sarcomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003293

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

21 January 2018

1 reference

12 December 2020

A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults

1 reference

12 December 2020

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma

1 reference

12 December 2020

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

12 December 2020

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline

1 reference

12 December 2020

Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

12 December 2020

High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma

1 reference

12 December 2020

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

1 reference

12 December 2020